While advances in immunotherapy have resulted in remarkable clinical responses in some patients, there will be >14 million new cases of cancer diagnosed in 2020 with >8 million deaths. Resistant and recurrent aggressive metastatic disease is the cause of <90% of these deaths in modern economic societies. Aberrant migration and proliferation of cancer cells are the hallmarks of tumor metastasis and resistant buildup therefore it is an attractive pathway for anti-cancer modalities.

BioKine is a private, well integrated, VC-funded and revenue garnering entity. Its leading product, BL-8040 (BKT-140) is co-developed with BiolineRx (NASDAQ:BLRX) for multiple indications, including: Stem Cell Mobilization (Ph-3) , AML (Ph-2b), Pancreatic Carcinoma in combo with Chemo and anti-PD-1/KEYTRUDA (Ph-2a). Biokine has developed a suite of unique technologies to target cancer- MigHit™ and ImmunHit™ -and is conducting advanced preclinical research on novel drug candidates discovered in-house.

Biokine is managed by a team of Biopharma veterans with a proven track records taking drugs from idea to advance clinical studies